key: cord-0967976-0soblqa3 authors: Metcalfe, Christopher; Dogan, Mehmet; Glazzard, Nina; Ross, Elizabeth; George, Ajith title: Introduction of a novel telescopic pathway to streamline 2‐week‐wait suspected head and neck cancer referrals and improve efficiency: A prospective service evaluation date: 2021-12-28 journal: Laryngoscope Investig Otolaryngol DOI: 10.1002/lio2.721 sha: 1b4703a24cc29a54fae9519d43e4472664287c23 doc_id: 967976 cord_uid: 0soblqa3 OBJECTIVES: This study summarizes the introduction of a novel telescopic pathway, which streamlines 2‐week‐wait suspected head and neck cancer referrals to our unit, describes the logistics of the pathway, and analyzes referral numbers and outcomes. We also discuss wider issues surrounding remote assessment in head and neck cancer. METHODS: Data were collected prospectively between January and May 2021, capturing all 2‐week‐wait referrals to our unit following the introduction of a telescopic pathway which utilized a nurse‐led clinic for nasendoscopic examination of selected patients and consultant‐led remote assessment using store and forward technology. Information on referral numbers, waiting times and outcomes was recorded. RESULTS: Three hundred and forty (185 high risk, 155 low risk) patients entered the telescopic pathway with the remaining 74 patients seen on the conventional standard of care pathway. Cancer conversion rates were 17%, <1%, and 5.4% for the high‐risk telescopic, low‐risk telescopic and standard of care pathways respectively. No patients discharged from the telescopic pathway were re‐referred within 3 months. Review capacity for endoscopic examination was higher per consultant on the telescopic pathway versus the standard of care (p = .01). CONCLUSION: A combination of risk stratification and asynchronous telescopic assessment shows promise for the management of suspected head and neck cancer referrals. Potential benefits include consultant‐led care for all patients and enhanced documentation. Digital communication with patients may also assist with adherence to the new NHS 28‐day diagnostic standard for cancer referrals. Ongoing data collection is required to assess how the pathway functions over a longer period. LEVEL OF EVIDENCE: 2c K E Y W O R D S COVID19, head and neck cancer, technology, telemedicine The novel coronavirus 19 disease (COVID19) pandemic has had a profound impact on the way we practice medicine in the United Kingdom, and this has been notable in the referral, assessment and management of suspected Head and Neck Cancer (HNC) patients. A nationwide lockdown implemented in March 2020 formed part of a strategy which aimed to reduce the potential impact of the pandemic on the National Health Service (NHS) and, as part of this, there was a reduction in our capacity to deliver timely and comprehensive elective services, including head and neck cancer care. The British Association of Head and Neck Oncologists (BAHNO) issued a position statement on delivering HNC care during the pandemic. 1 With regards to suspected HNC referrals, their focus was on the identification and prioritization of "high-risk" patients likely to have a malignancy and minimizing hospital exposure in patients who are frail or those with significant comorbidities. BAHNO also advocated the use of a validated head and neck cancer risk calculator to assist with patient stratification. 2 While many centers saw a reduction in the number of 2-week-wait head and neck referrals during the early stages of the pandemic, 3 referral numbers have now increased and are at prepandemic levels in our unit. These unprecedented pressures on the HNC pathway have served as a stimulus for the development of new methods of service delivery, such as the use of telephone triage, 4, 5 to optimize patient care. The COVID19 pandemic has also coincided with an evolution in NHS cancer targets, via the introduction of a new Faster Diagnosis Standard, introduced in April 2020, to ensure that all patients who are referred for the investigation of suspected cancer find out, within 28 days, if they do or do not have a cancer diagnosis. 6 Currently, cancer referrals in the United Kingdom are held against the standard outlined in the Cancer Reform Strategy. 7 This means all suspected cancer patients should be seen by a specialist within 14 days of referral, patients should wait no longer than 31 days between diagnosis or decision to treat and commencement of treatment and patients should wait no longer than 62 days between the initial referral and commencement of treatment. The new Faster Diagnosis Standard should lead to a reduction in the time between referral and diagnosis with a subsequent improvement in clinical outcomes for those with cancer and a reduction in anxiety for those patients waiting for an "all clear." A combination of pandemic recovery and the need to adhere to the new 28-day diagnostic standard has provided impetus to optimize and refine suspected HNC referrals to our unit. Evidence already exists to suggest that remote assessment using telemedicine may be a feasible option in ENT. [8] [9] [10] [11] Indeed, a visual examination of the upper aerodigestive tract, usually in the form of flexible nasendoscopy and oral examination with a headlight, is essential for the assessment of suspected HNC patients. Both the acquisition of high-quality images and the development of technology, which allows secure storage and forwarding of such images facilitates an environment in which senior clinicians can provided a comprehensive clinical assessment entirely remotely. This paper summarizes the introduction of a novel telescopic pathway which streamlines 2-week-wait suspected HNC referrals to our unit, describes the logistics and equipment used on the pathway and analyzes referral numbers, waiting times, clinical outcomes, and cancer conversion rate. The novel pathway is compared with our current standard of care. We also discuss wider issues surrounding the use of remote assessment, the advantages and disadvantages of such a pathway and areas in which further research are required. All 2-week-wait (TWW) referrals allocated to two consultant head and neck surgeons at our center between January 2021 and May 2021 were reviewed by those consultants. Unexplained neck lump referrals were diverted directly for imaging prior to review and remaining referrals were triaged into high-and low-risk based on a validated head and neck cancer risk calculator (http://www.orlhealth. com/risk-calculator-2.html). 2 Triage was carried out based on the written referral. This calculator has been validated on over 10,000 patients and was endorsed by ENT UK for referral triage during the COVID19 pandemic. 4 High-risk patients were seen face-to-face by one of two head and neck consultants (teleconsultants 1 and 2). Lowrisk patients were diverted to a telescopic clinic led by a trained advanced nurse practitioner (ANP) and reviewed as soon as possible. During this consultation, a flexible nasendoscopy and an oral examination was performed and recorded using store and forward technology (see below for equipment details). This information was then reviewed by either teleconsultant 1 or 2 and a summary sheet, which included history, endoscopic images and outcome, was generated within 48 h. This summary was automatically uploaded onto the digital patient records system and forwarded to both the patient (via text message, if mobile number provided) and the general practitioner (GP). A summary of the telescopic pathway is shown in Figure 1 . All TWW referrals to a third consultant head and neck surgeon between January 2021 and May 2021 were reviewed by a single senior head and neck surgeon. Unexplained neck lump referrals were diverted directly for imaging prior to review and remaining referrals were booked into the next available face-to-face clinic for review, either by that consultant or a supporting registrar. Where possible, these were all seen within 2 weeks as per the conventional cancer pathway. All images were acquired using a standard fiberoptic flexible nasendoscope (DP Medical) attached to an iPhone SE2 (Apple Inc.) using an endoscope-smartphone adapter (endoscope-i Ltd). This iPhone was a managed device which was secured by endoscope-i and therefore could only be used for image capture and storage using the secure hospital network. Images were viewed, recorded and stored using the e-i Pro application (endoscope-i Ltd) in accordance with trust protocol. Videos stored on this device were then accessible by the reviewing consultant using a corresponding iPad (8th generation, Apple Inc.) equipped with a bespoke software that allows the user to view captured images at 60 frames-per-second (FPS), choose and store stills from the video and generate a summary document which includes four stills alongside a diagnosis and outcome. The equipment used on the telescopic pathway is demonstrated in Figure 2 . Data were collected prospectively between January 2021 and May 2021, capturing all TWW referrals to our unit. Information on referral numbers, patient demographics, waiting times, radiological investigation, diagnostic surgery and cancer diagnosis rates were recorded, for both the telescopic and standard of care pathway. Data were entered into Microsoft Excel and a descriptive analysis was undertaken reporting referral numbers, investigations, theater F I G U R E 1 Summary of telescopic pathway F I G U R E 2 Demonstration of the equipment being used on the low-risk telescopic pathway conversion rate and cancer conversion rate for each part of the telescopic pathway and the standard of care. IBM SPSS Statistics (version 27) was used to conduct tests of normality and one-way ANOVA to compare the number of patients reviewed on the standard of care pathway and the two teleconsultant groups. The new pathway was set up as a quality improvement project to help manage pressures on the head and neck cancer pathway, and therefore this project was registered with and approved by the clinical governance department at our unit. As this work was evaluating a trustapproved service, ethical approval was not required. There were 661 TWW referrals to our unit between January 2021 and May 2021. Two hundred and forty seven (37.4%) of these were for unexplained neck lumps and were diverted for imaging prior to review. (Table 1) . Overall cancer conversion rate was 11% with 21% of patients requiring a diagnostic procedure in theater. Of the 340 patients on the telescopic pathway, 185 (54.4%) were deemed to be high-risk, based on the risk calculator. These patients were seen by a consultant in a face-to-face clinic for nasendoscopy within 5 days. Within this cohort, there were 31 positive cancer diagnoses, giving a conversion rate of 17%. Fifty five patients were listed for a diagnostic procedure, giving a theater conversion rate of 30%. Outcomes for the triaged high-risk patients are summarized in Table 2 . No patients were re-referred into the system, due to progressive symptoms, within 3 months. Of the 340 patients on the telescopic pathway, 155 (45.6%) were seen in a nurse-led nasendoscopy clinic, including 80 (23.5%) new primary care referrals who were in the low-risk category as per the calculator, 45 (13.2%) patients who required nasendoscopy following imaging, 14 (4.1%) follow-up scopes for high-risk patients, 13 (3.8%) patients referred internally by another department and 3 (0.88%) reviews following scans. The 80 new primary care referrals waited for a mean of 15.3 days (range 2-48) for a review. Of these, five required a diagnostic procedure in theater, giving a theater conversion rate of 6%. 21 (26.3%) required imaging. There was one positive cancer diagnosis giving a cancer conversion rate of <1%. None of the patients with a negative cancer diagnosis were re-referred into the system within 3 months of discharge. Due to progressive symptoms, and all but three of them received an outcome within 28 days. Of the three that did not, one patient did not attend their initial appointment, one patient was missed due to an administrative error and one patient breeched. Outcomes for the low-risk patients on the telescopic pathway are summarized in Table 3 . There were 74 patients on the standard of care pathway who were seen at the next available face-to-face appointment once neck lump referrals had been diverted for imaging. Patients were seen in a faceto-face clinic within a mean of 14.0 days (range 2-56). Ten patients required a diagnostic procedure in theater, giving a theater conversion This paper describes the introduction of a novel telescopic pathway for the assessment of TWW suspected head and neck cancer referrals to our unit. As far as the authors are aware, this type of pathway is not currently being used elsewhere within the NHS and therefore the presented data provides information on the feasibility of such a service and the likely impact on the patient journey. It also gives some indication of the potential benefits of such a service while providing an opportunity to explore equipment requirements, the logistics of transferring to a telescopic service and wider issues raised by the introduction of a remote assessment pathway. and by allied members of the HNC team, for example, speech and language therapists. If the patient requires a diagnostic procedure in theater, these images can serve as an aide memoire for the surgeon on the day of surgery to refamiliarize themselves with the patient's pathology and may also help the anesthetist with planning of airway management. Utilizing these images in the patient records also ensures accountability for the outcome generated post assessment. such as physicians associates, may also be an option. While early results from the implementation of our telescopic HNC pathway are encouraging, there are a number of areas in which further work is required. Firstly, ongoing data collection is needed as our pathway develops to provide greater numbers for analysis. Additionally, COVID19 recovery, health care demand and the potential for further disruptions from COVID19 variants means the NHS is in a volatile state, and therefore more data are required on how the pathway will cope with increased referral numbers and the potential for staff absences, among other things. There may also be a reluctance for NHS consultants to pick up extra clinics, due to the unresolved issues with potential pensions tax implications, and this may affect how the telescopic pathway is utilized. It is also imperative to seek feedback, in the form of qualitative studies, from key stakeholders, including patients and health care professionals in the wider head and neck community to better inform the development of a telescopic service. Health economic analysis would also provide more information on the long-term sustainability of this service within the current NHS model. A combination of risk stratification and asynchronous telescopic assessment shows promise as a novel pathway for the management of 2-week-wait suspected HNC referrals. Potential benefits include consultant-led care for all patients, optimized utilization of consultant time and focused learning opportunities for trainees. Digital communication with patients may also assist with adherence to the new NHS 28-day diagnostic standard for cancer referrals and storage of digital images as part of patient records may optimize communication across the multidisciplinary team. Ongoing data collection is required to provide larger numbers for analysis and to assess how the pathway functions over a longer period. Further research is required in the form of qualitative assessments which seek the feedback of key stakeholders, including patients, to better inform the development of a telescopic service. Thank to you the staff at University Hospitals North Midlands for their assistance with the introduction of the new pathway. Mr. Ajith George is the Medical Director of endoscope-i Ltd, a developer of physical adaptors and smartphone applications for mobile endoscopic imaging. https://orcid.org/0000-0002-8790-2722 BAHNO. Statement on Covid-19. Accessed Head and neck cancer risk calculator (HaNC-RC)-V.2. Adjustments and addition of symptoms and social history factors-PubMed The impact of coronavirus disease 2019 on head and neck cancer services: a UK tertiary centre study Remote triaging of urgent suspected head and neck cancer referrals during Covid-19 pandemic Telephone triage of suspected head and neck cancer patients during the coronavirus disease 2019 pandemic using the head and neck cancer risk calculator version 2 Cancer Reform Strategy Head and neck cancer assessment by flexible endoscopy and telemedicine Community triage of otology patients using a store-and-forward telemedicine device: a feasibility study A systematic review of outcomes of remote consultation in ENT A systematic review of remote otological assessment using video-otoscopy over the past 10 years: reliability and applications Head and neck oncology during the COVID-19 pandemic: reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks Head and neck cancer surgery during the COVID-19 pandemic: an international, multicenter, observational cohort study Remote triage incorporating symptom-based risk stratification for suspected head and neck cancer referrals: a prospective population-based study Artificial intelligencebased methods in head and neck cancer diagnosis: an overview Confident texture-based laryngeal tissue classification for early stage diagnosis support National Cancer Waiting Times Monitoring Dataset Guidance-Version 11.0 Delivering a net zero NHS A prospective assessment of nasopharyngolaryngoscope recording adaptor use in residency training. Otolaryngol-Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg Introduction of a novel telescopic pathway to streamline 2-week-wait suspected head and neck cancer referrals and improve efficiency: A prospective service evaluation